Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$816.65
-$12.78 (-1.5%)
Closing Price on November 6, 2024
REGN Articles
June 22, 2016: Here are four stocks trading with relatively heavy volume among 40 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 5 to 4 while Nasdaq...
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo and Vivint Solar.
Published:
Last Updated:
Regeneron Pharmaceuticals has announced that two Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their...
Published:
Last Updated:
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
Published:
Last Updated:
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3...
Published:
Last Updated:
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
Regeneron Pharmaceuticals reported disappointing fourth-quarter financial results before the markets opened on Tuesday.
Published:
Last Updated:
Regeneron Pharmaceuticals seems to have held up rather well against an analyst downgrade on Wednesday.
Published:
Last Updated:
Wednesday's top analyst calls include Apple, AT&T, DuPont, Fitbit, Huntington Bancshares, McDonald's, Merck, Newmont Mining and Sprint.
Published:
Last Updated:
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Published:
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
Published:
Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.
Published:
Monday was historic. But these types of movements are not one off. They usually come in clusters.
Published:
Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock performance.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Cheniere Energy, First Solar, Hilton Worldwide, National Oilwell Varco and Disney.
Published: